Skip to main content
. 2016 Mar 30;9(2):89–104. doi: 10.1111/cts.12391

Figure 4.

Figure 4

The role of modeling and simulation in combination immunotherapy development. (a) Modeling and simulation approaches used to answer questions during preclinical and clinical development and life‐cycle management. (b) Iterative cycle between experimentation, modeling, prediction, analysis, and the generation of new, testable hypotheses. LCM, life‐cycle management; FIH, first‐in‐human; PD, pharmacodynamics; PKPD, pharmacokinetics/pharmacodynamics; PBPK model, physiologically based pharmacokinetic model; DDI, drug–drug interaction.